1. Market Research
  2. > Pharmaceutical
  3. > Therapy
  4. > Oncology Market Trends
  5. > Competitor Analysis: Cancer Vaccines

Competitor Analysis: Cancer Vaccines

  • March 2014
  • -
  • La Merie Publishing
  • -
  • 179 pages

Cancer Vaccines
The present Competitive Intelligence report about Cancer Vaccines provides a competitor evaluation in the field of novel prophylactic and therapeutic vaccines to fight cancer as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Projects are listed according to their main antigenic constituents: peptides, recombinant proteins, idiotype antibody, DNA (plasmid, expression vector), RNA, virus-like particles (VLP), dendritic cells, tumor cells (tumor cell lines), microorganism-based and others.

Of the 140 clinical stage cancer vaccines, three were approved and are commercialized in the major pharmaceutical markets with combined 2013 sales of US$ 2,385 mln. Peptides and proteins make out 43% of clinical stage cancer vaccines, followed by dendritic cell and tumor cell (line)-based cancer vaccines with each contributing 15% to the clinical cancer vaccine pipeline. DNA- and RNA-based cancer vaccines maked out 17% of the clinical portfolio.

The report includes a compilation of currently active projects in research and development for prophylaxis and therapy of cancer. In addition, the report lists company-specific R&D pipelines of cancer vaccines. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,

• Target / Mechanism of Action,

• Class of Compound,

• Company,

• Product Category,

• Indication,

• R&D Stage and

• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: Cancer Vaccines
Table of Contents
1. Cancer Vaccines by Main Composition

- Peptide-based Cancer Vaccines
- Protein-based Cancer Vaccines
- Idiotype Antibody-based Cancer Vaccines
- DNA-based Cancer Vaccines: naked and virally vectored
- RNA-based Cancer Vaccines
- Virus-Like Particle (VLP)-based Cancer Vaccines
- Dendritic Cell-based Cancer Vaccines
- Tumor Cell and Tumor Cell Line - based Cancer Vaccines
- Microorganism-based Cancer Vaccines
- Other and Not Defined Cancer Vaccines

2.  Corporate Cancer Vaccines RandD Pipelines

Competitor Analysis: Cancer Vaccines

Related Companies
ABIVAX
Activartis
Aduro BioTech
Advanced Cancer Therapeutics
Advaxis
Aeterna Zentaris
Agenus
Antigen Express
ApoVax
Ascend Biopharmaceuticals
Asterias Biotherapeutics
Avax Technologies
Bavarian Nordic
Bellicum Pharmaceuticals
Bharat Biotech
Biocon
BioLife Science
BioNTech
Biontech RNA Pharmaceuticals
Biovest International
Celgene
Celldex Therapeutics
Cellular Biomedicine
CSL
CureVac
Dainippon Sumitomo Pharma
DCPrime
Delta-Vir
Dendreon
Etubics
Galena Biopharma
Genexine
Genticel
GlaxoSmithKline
Gliknik
GlobeImmune
Gradalis
H. Lee Moffitt Cancer Center and Research Institute
Heat Biologics
Icon Genetics
Immatics biotechnologies
Immune Design
Immunicum
ImmunoCellular Therapeutics
ImmunoFrontier
Immunovaccine
Immunovative Therapies
Immutep
Innate Immunotherapeutics
Inovio Pharmaceuticals
ISA Pharmaceuticals
KAEL-GemVax
MabVax
Mayo Clinic
MediGene
Mediolanum
Merck
Merck Serono
Mologen
Momotaro-Gene
NewLink Genetics
Northwest Biotherapeutics
Novartis
NovaRx
Ohio State University Comprehensive Cancer Center
Oncopep
OncoTherapy Science
Oncothyreon
Oncovir
Ono Pharmaceutical
Oryx
Otsuka Pharmaceutical
Oxford BioMedica
PDS Biotechnology
Polynoma
Prima Biomed
Profectus BioSciences
Roche
Scancell
Shanghai Zerun Biotech Co
Shenyang Sunshine Pharmaceutical Co (3SBio)
Shiga University
Shionogi
Sidney Kimmel Comprehensive Cancer Center
Stemline Therapeutics
TapImmune
Targovax
Transgene
Ultimovacs
University Hospital Grenoble
University of Arkansas
Vaccibody
Vaccinex
Vaccinogen
Vaxart
Vaxil Biotherapeutics
VAXIMM
Vaxon Biotech
ViroMed
Xiamen Innovax Biotech
Zensun Sci and Tech Co

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Immunotherapy Drugs Market by Type of Drugs, Therapy Area, End-User, Region - Global Forecast to 2021

Immunotherapy Drugs Market by Type of Drugs, Therapy Area, End-User, Region - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The global immunotherapy drugs market is projected to reach USD 201.52 billion by 2021 from USD 108.41 billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021. In this report, ...

Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19

Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19

  • $ 4995
  • Industry report
  • November 2016
  • by GBI Research

Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19 Summary Cancer vaccines are being ...

Global Cancer Immunotherapies Market to 2022 - Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market

Global Cancer Immunotherapies Market to 2022 - Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market

  • $ 4995
  • Industry report
  • December 2016
  • by GBI Research

Global Cancer Immunotherapies Market to 2022 - Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market Summary Cancer is a group of diseases characterized ...


Download Unlimited Documents from Trusted Public Sources

Cancer Immunotherapy Market in the US

  • February 2017
    7 pages
  • Cancer Immunoth...  

    Monoclonal Anti...  

  • United States  

View report >

Cancer Immunotherapy Market in the US

  • February 2017
    10 pages
  • Cancer Immunoth...  

  • United States  

View report >

Cancer Immunotherapy Market in the US

  • February 2017
    8 pages
  • Cancer Immunoth...  

    Monoclonal Anti...  

  • United States  

View report >

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.